Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Data Integrity in Equipment Qualification: Audit Trail Gaps Leading to FDA and EMA Findings

When Zamann engaged with a German pharmaceutical manufacturer to improve compliance with EMA and FDA expectations for Equipment Qualification (EQ), a critical issue surfaced immediately. The company lacked reliable data integrity controls within the qualification lifecycle.

Audit trails existed, yet no one reviewed them. Electronic records were generated, yet teams ignored verification. User permissions existed, yet roles remained misaligned. Raw data was stored, yet no one could confirm its location.

Therefore, this was not a minor technical gap. Instead, it represented a GMP failure classified as critical by regulators. Consequently, the qualification process itself became unreliable.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Regulatory Scrutiny: The system operated under strict FDA and EMA oversight. Therefore, any data integrity gap directly increased the risk of inspection findings and enforcement actions.
  • Lack of Data Integrity Controls: Although systems had audit trails and electronic records, controls were ineffective. As a result, traceability, accountability, and data reliability were compromised.
  • Misconfigured User Access: User roles did not align with responsibilities. Consequently, unauthorized changes could occur without proper traceability.
  • Uncontrolled Data Management: Raw data was stored across local systems. Therefore, the company could not guarantee data location, integrity, or completeness.
  • Absence of Lifecycle Integration: No formal procedure defined how data integrity should apply across the equipment qualification lifecycle. As a result, gaps existed from URS to PQ.
  • Time and Operational Pressure: The organization needed rapid alignment with regulatory expectations. However, the scale of deficiencies made remediation complex and time-sensitive.

Zamann Pharma Support’s Approach

  • Project Initialization: First, Zamann conducted a structured kickoff with all stakeholders. This clarified objectives, timelines, and key compliance risks.
  • Comprehensive Data Integrity Assessment: Next, the team evaluated data integrity controls across the entire qualification lifecycle. This included audit trails, user access, electronic records, and raw data handling.
  • Regulatory Benchmarking: Zamann aligned findings against FDA (21 CFR Part 11, Part 211) and EMA (Annex 11, Annex 15) requirements. Therefore, each gap directly mapped to regulatory expectations.
  • Detailed Gap Identification: The team identified critical weaknesses in audit trail review, access control, backup testing, and electronic record integrity. In addition, poor traceability and lack of formal data integrity procedures created major compliance gaps.
  • Structured Risk Evaluation: Zamann evaluated each gap based on qualification validity, data reliability, and inspection readiness. This directly linked system weaknesses to potential FDA and EMA findings.
  •  
  • Corrective and Preventive Actions (CAPA): CAPAs included audit trail review procedures, role-based access control, backup testing, and data integrity validation. In addition, training and lifecycle integration of DI principles were implemented.
  • Implementation Support: Zamann provided templates, training workshops, and progress tracking. This ensured structured, transparent, and controlled CAPA execution.

Results Achieved

  • Regulatory Compliance Restored: The company aligned its qualification process with FDA and EMA data integrity expectations. As a result, inspection risk significantly decreased.
  • Reliable Qualification Data: Data integrity controls ensured that qualification results became traceable, accurate, and reproducible. Therefore, the validated state could be justified.
  • Risk Reduction: By addressing critical DI gaps, the company reduced the likelihood of regulatory findings, product risks, and enforcement actions.
  • Improved Operational Efficiency: Clear procedures and controlled systems reduced rework, repeated testing, and investigation delays. Consequently, timelines stabilized.
  • Stronger Internal Capabilities: Through training and workshops, teams developed a deeper understanding of ALCOA+ principles and regulatory expectations.
  • On-Time Remediation: Despite the complexity, Zamann completed the assessment and CAPA plan within the required timeframe. Therefore, the client met internal and regulatory deadlines.
Laboratory
GMP qualification and lifecycle validation activities including IQ, OQ, and PQ supporting inspection readiness in pharmaceutical manufacturing.
Services

Qualification and Validation for GMP Systems

Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. Why do audit trails fail to support qualification decisions during inspections?

Because teams often enable audit trails but do not review them. As a result, critical events remain undetected, and regulators consider the data unreliable. Without documented review procedures and trained reviewers, audit trails lose their compliance value.

 

2. How does poor access control impact qualification outcomes?

If user roles do not match responsibilities, unauthorized changes can occur without traceability. Therefore, qualification data may be altered or overwritten. This directly invalidates OQ/PQ results and raises critical data integrity concerns.

 

3. What is the biggest data integrity risk in equipment qualification lifecycle?

The absence of lifecycle integration. When DI controls are not embedded from URS to PQ and periodic review, gaps accumulate. Consequently, even if individual tests pass, the overall qualification cannot be trusted by regulators.